thalidomide has been researched along with Neoplasms, Pleural in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment." | 9.17 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM)." | 9.11 | Thalidomide in patients with malignant pleural mesothelioma. ( Baas, P; Boogerd, W; Custers, F; Dalesio, O; Haringhuizen, A; van Zandwijk, N, 2005) |
| "In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment." | 5.17 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM)." | 5.11 | Thalidomide in patients with malignant pleural mesothelioma. ( Baas, P; Boogerd, W; Custers, F; Dalesio, O; Haringhuizen, A; van Zandwijk, N, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yeoh, KW | 1 |
| Thitsar, SM | 1 |
| Master, Z | 1 |
| Loh, Y | 1 |
| Chen, Y | 1 |
| Nagarajan, C | 1 |
| Tin, KM | 1 |
| Cutter, D | 1 |
| Mikhaeel, G | 1 |
| Buikhuisen, WA | 1 |
| Burgers, JA | 1 |
| Vincent, AD | 1 |
| Korse, CM | 1 |
| van Klaveren, RJ | 1 |
| Schramel, FM | 1 |
| Pavlakis, N | 2 |
| Nowak, AK | 1 |
| Custers, FL | 1 |
| Schouwink, JH | 1 |
| Gans, SJ | 1 |
| Groen, HJ | 1 |
| Strankinga, WF | 1 |
| Baas, P | 2 |
| Pass, HI | 1 |
| Chen, JR | 1 |
| Tzen, CY | 1 |
| Yang, YC | 1 |
| Dhalluin, X | 1 |
| Scherpereel, A | 1 |
| Kao, SC | 1 |
| Vardy, J | 1 |
| Harvie, R | 1 |
| Chatfield, M | 1 |
| van Zandwijk, N | 2 |
| Clarke, S | 1 |
| Boogerd, W | 1 |
| Dalesio, O | 1 |
| Haringhuizen, A | 1 |
| Custers, F | 1 |
1 review available for thalidomide and Neoplasms, Pleural
| Article | Year |
|---|---|
Chemotherapy and radiotherapy for mesothelioma.
Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deac | 2011 |
3 trials available for thalidomide and Neoplasms, Pleural
| Article | Year |
|---|---|
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ca | 2013 |
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Protein; Female; | 2013 |
Thalidomide in patients with malignant pleural mesothelioma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female | 2005 |
3 other studies available for thalidomide and Neoplasms, Pleural
| Article | Year |
|---|---|
Pleural plasmacytomas - the role of radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cycloph | 2020 |
Mesothelioma: closer to the target?
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neopla | 2013 |
Metronomic paclitaxel and thalidomide for rapidly metastatic primary vulvar malignant rhabdoid tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2009 |